AI in Drug Discovery Funding Tracker (200+ deals)

Building a startup or looking for your next investment in AI in drug discovery? Our report gives you the full picture.
Summary
AI drug discovery startups raised at least $14.1B across 226 deals involving 164 companies. Isomorphic Labs raised $2.7B in 2 rounds, the most of any company we tracked.
That makes AI drug discovery a serious market. But the 53 rounds above $50M accounted for 23% of deals and at least $11.3B of the disclosed money. A few giant checks do much of the work.
Most founders see much smaller amounts. The median disclosed round was $25M, and 208 financings had a public amount. A billion-dollar launch remains exceptional.
The money also follows different kinds of science. Generative small-molecule developers and therapeutic protein designers attract the largest commitments, partly because they can move from AI models to drug candidates.
Drugmakers are testing those capabilities. Isomorphic Labs works with Novartis, Lilly and Johnson & Johnson, Chai Discovery has announced pharmaceutical collaborations, and Enveda is advancing medicines from its discovery platform into clinical testing.
The gap between early and late rounds is large. Seed deals are common, but companies developing their own medicines need much bigger checks as experiments and patient trials become more expensive.
Investors also return to a smaller group of companies. We found 114 companies with just 1 deal, while 50 companies raised more than once. A steady supply of new startups does not mean equal access to follow-on capital.
North America attracted 120 deals and at least $9.1B, while Europe recorded 67 deals and at least $3.9B. Britain has a strong position in the market, although its biggest developer has an outsized impact on those totals.
Funding arrives regularly even when the headlines go quiet. Across 34 completed months, every month had a recorded financing. The median month had 6 deals and $237M, with occasional giant rounds sending totals far higher.
Today, investors are paying for more than clever models. They are backing experiments, private biological data and medicines with a chance of reaching patients. Those medicines will need to succeed in trials before the biggest bets can be judged.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us

In our report covering the AI drug discovery market, you will always find fresh funding data, taken straight from our own verified funding database.
Our funding tracker covering the ai drug discovery market
Below is the table listing all the deals. You can find our methodology at the end of this page.
If you want a deeper understanding of the market and its current dynamics, get our ai drug discovery market report.
| Company | Category | Date | Stage | Deal size | What they do | Region | Lead investors | Country | Rank |
|---|---|---|---|---|---|---|---|---|---|
| Orakl Oncology | AI Phenotypic & Functional Screening | November 2026 | Series A | $34M | Combines AI with patient-derived tumor organoid screens to select preclinical oncology drugs and uncover biological co-targets. | Europe | Norrsken VC, Singular | France | |
| PsiThera | AI Hit Discovery & Lead Generation | November 2026 | Unknown | $25M | AI-designed medicines for difficult protein targets | North America | Not disclosed | United States | |
| SRTD biotech | AI Therapeutic Biologics / Protein Design | November 2026 | Seed | ~$36M | Uses AI-driven RNA-marker identification and construct design to generate cell-selective mRNA therapeutics. | Europe | Mérieux Equity Partners, NRW.BANK, Boehringer Ingelheim Venture Fund | Germany | |
| Sanyou Bio | AI Therapeutic Biologics / Protein Design | November 2026 | Series C | ~$15M | Runs AI-guided antibody discovery and engineering through its AI-STAL library and wet-lab/dry-lab drug-accelerator platform. | Asia-Pacific | Not disclosed | China | |
| Araceli Biosciences | AI Phenotypic & Functional Screening | November 2026 | Unknown | $4.5M | Provides AI-assisted high-content cellular imaging and phenotypic analysis for preclinical drug screening. | North America | Not disclosed | United States | |
| Venomics AI | AI Therapeutic Biologics / Protein Design | November 2026 | Seed | $2.7M | Uses AI and experimental screening of animal-venom peptides to identify and optimize therapeutic leads. | Asia-Pacific | Speciale Invest, South Park Commons | India | |
| Signet Therapeutics | AI Phenotypic & Functional Screening | November 2026 | Series A | $25M+ | Combines patient-derived organoid cancer models and AI to discover and preclinically validate targeted therapies. | Asia-Pacific | China Life Equity Investment | China | |
| Ribopeutic | AI Target & Causal Biology Discovery | October 2026 | Series A | Undisclosed | Uses AI to predict RNA structures and identify druggable RNA targets for small-molecule discovery. | Asia-Pacific | Loyal Valley Capital, Sinovation Ventures | China | |
| ALLOX | AI Hit Discovery & Lead Generation | October 2026 | Seed | $10M | Combines AI prediction and functional biophysical data to discover druggable allosteric sites and design small-molecule drug leads. | Europe | Asabys Partners | Spain | |
| Atlas Bio | Preclinical Predictive AI & Autonomous DMTA | October 2026 | Seed | $10M | Uses a human-transcriptomics foundation model to predict drug-response biology and select preclinical development paths without animal trials. | Europe | Creandum | Switzerland | |
| Pathos AI | AI Target & Causal Biology Discovery | October 2026 | Series D+ | $237M | Uses agentic AI and human disease data to identify therapeutic assets, test disease-biology hypotheses and guide oncology drug development. | North America | Bristol Myers Squibb | United States | |
| Zhichong Pharma | Generative Small-Molecule Design | October 2026 | Series A | Undisclosed | Uses AI models to design therapeutic molecules for veterinary drug discovery and preclinical development. | Asia-Pacific | Tianhui Capital | China | |
| Warp Sciences | Preclinical Predictive AI & Autonomous DMTA | October 2026 | Series A | $215M | Runs AI- and robotics-assisted medicinal chemistry labs that synthesize and test compound analogues during preclinical lead optimization. | North America | Lightspeed Venture Partners | United States | |
| Model Medicines | Generative Small-Molecule Design | October 2026 | Unknown | $5.1M | AI-designed drugs for infectious diseases | North America | Not disclosed | United States | |
| Undecimal Bio | AI Lead Optimization & Medicinal Chemistry | October 2026 | Seed | $18M | Uses AI and high-throughput biological screening to design ligand conjugates that deliver siRNA drug candidates beyond the liver. | Europe | 4BIO Capital, IQ Capital | United Kingdom | |
| LigIT | AI Therapeutic Biologics / Protein Design | October 2026 | Seed | Undisclosed | Uses generative AI to design novel peptide therapeutics and progress candidates from hits to preclinical leads. | Asia-Pacific | Not disclosed | China | |
| Rivercell | Preclinical Predictive AI & Autonomous DMTA | October 2026 | Seed | $25M | Builds AI virtual-cell models trained on experimental perturbation data to predict cellular drug response and toxicity before human trials. | Europe | HV Capital | France | |
| WhiteLab Genomics | AI Therapeutic Biologics / Protein Design | October 2026 | Series B | $26M | Uses AI models to design viral delivery vectors and programmable payloads for genomic therapeutics. | Europe | AVP | France | |
| Biossil | AI Repurposing / Indication Selection | September 2026 | Unknown | $153M | Uses AI to identify and redevelop previously abandoned drug candidates for new therapeutic applications. | North America | OpenAI Startup Fund | Canada | |
| HITS | AI Hit Discovery & Lead Generation | September 2026 | Series B | ~$13M | Offers HyperLab, an AI drug-discovery platform for virtual screening, lead design and preclinical molecular-property prediction. | Asia-Pacific | Premier Partners | South Korea | |
| BigHat Biosciences | AI Therapeutic Biologics / Protein Design | September 2026 | Series C | $75M | AI-driven antibody and protein engineering | North America | DFJ Growth, Premji Invest | United States | |
| Basecamp Research | AI Therapeutic Biologics / Protein Design | September 2026 | Series C | $140M | Biodiversity-trained AI protein design models | Europe | S32 | United Kingdom | |
| Big Picture Bio | AI Repurposing / Indication Selection | September 2026 | Seed | ~$2M | Uses generative world models to design and optimize preclinical cancer drug combinations and treatment sequences. | Europe | Kadmos Capital, Exceptional Ventures | United Kingdom | |
| Anew Labs | AI Therapeutic Biologics / Protein Design | September 2026 | Series A | $290M | AI designed therapeutic proteins and drugs | Asia-Pacific | HongShan, IDG Capital, Hillhouse Investment, 5Y Capital | China | |
| Mithrl | AI Target & Causal Biology Discovery | September 2026 | Series A | $20M | Develops an AI biomedical research platform that helps scientists identify therapeutic targets and evaluate disease mechanisms. | North America | Obvious Ventures | United States | |
| NUTSHELL Therapeutics | Generative Small-Molecule Design | September 2026 | Series C | Undisclosed | Uses an AI- and physics-based platform to design allosteric small-molecule therapeutics. | Asia-Pacific | Trustar Capital, Decheng Capital | China | |
| Moonwalk Biosciences | AI Target & Causal Biology Discovery | September 2026 | Series B | $70M | Epigenetic and RNAi therapeutic discovery | North America | Alpha Wave Global, YK Bioventures | United States | |
| Superluminal Medicines | Generative Small-Molecule Design | September 2026 | Series B | $60M | AI-designed GPCR-targeted medicines | North America | BVF Partners | United States | |
| AIPher | AI Hit Discovery & Lead Generation | September 2026 | Seed | $14M | AI platform for drug discovery | Asia-Pacific | Xiang He Capital | China | |
| Enveda Biosciences | AI Hit Discovery & Lead Generation | September 2026 | Series D+ | $311M | AI discovery of nature-derived medicines | North America | Catalio Capital Management | United States | |
| Axiom Therapeutics | AI Lead Optimization & Medicinal Chemistry | August 2026 | Unknown | $12M | AI-designed therapeutics for difficult drug targets | Europe | Not disclosed | United Kingdom | |
| Aureka Biotechnologies | Generative Small-Molecule Design | August 2026 | Series B | $100M | AI foundation models for therapeutics | North America | Granite Asia | United States | |
| Engine Biosciences | AI Target & Causal Biology Discovery | August 2026 | Series B | $5M | AI drug target discovery platform | Asia-Pacific | GV | Singapore | |
| Chemify | Preclinical Predictive AI & Autonomous DMTA | July 2026 | Series B | $5.8M | Automated AI-powered molecular synthesis | Europe | Not disclosed | United Kingdom | |
| Transcripta Bio | AI Repurposing / Indication Selection | July 2026 | Series A | $24M | AI-guided drug discovery platform | North America | Not disclosed | United States | |
| Sightera Biosciences | Generative Small-Molecule Design | July 2026 | Seed | ~$3.4M | AI-designed drugs from patient-derived biology | Europe | Entourage, Anacura, Qbic | Belgium | |
| Chai Discovery | AI Therapeutic Biologics / Protein Design | July 2026 | Series C | $400M | AI foundation models for molecular design | North America | Index Ventures | United States | |
| Drug Farm | AI Target & Causal Biology Discovery | July 2026 | Series D+ | $55M | AI-assisted immunology drug development | Asia-Pacific | Shanghai Pudong Leading Area Investment Center, Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise | China | |
| Alchemab Therapeutics | AI Therapeutic Biologics / Protein Design | July 2026 | Series A | $32M | AI-enabled protective antibody drug discovery | Europe | British Business Bank | United Kingdom | |
| MindRank AI | AI Lead Optimization & Medicinal Chemistry | July 2026 | Series B | $52M | AI-native clinical drug development | Asia-Pacific | Not disclosed | China | |
| LifeMine Therapeutics | AI Hit Discovery & Lead Generation | July 2026 | Series D+ | $188M | Fungal-derived therapeutic drug discovery | North America | Milky Way Investments | United States | |
| Integrated Biosciences | AI Hit Discovery & Lead Generation | July 2026 | Unknown | $68M | AI discovery of drugs targeting aging | North America | Not disclosed | United States | |
| Xellar Biosystems | Preclinical Predictive AI & Autonomous DMTA | June 2026 | Series A | $50M | AI-powered human cellular modeling | North America | Not disclosed | United States | |
| Graph Therapeutics | AI Target & Causal Biology Discovery | June 2026 | Seed | $5M | AI drug discovery for inflammatory diseases | Europe | Daphni | Austria | |
| Gero | AI Target & Causal Biology Discovery | June 2026 | Series B | $17M | AI discovery of drugs for aging diseases | Asia-Pacific | Not disclosed | Singapore | |
| NewLimit | AI Target & Causal Biology Discovery | June 2026 | Series C | $435M | Develops epigenetic rejuvenation medicines | North America | Founders Fund | United States | |
| Protuoso Biosciences | AI Therapeutic Biologics / Protein Design | May 2026 | Seed | $9.5M | Engineered multifunctional proteins for therapeutic drugs | North America | Taya Venture, Darwin Ventures | United States | |
| 20n Bio | AI Hit Discovery & Lead Generation | May 2026 | Seed | $7.5M | AI-designed protein therapeutics | North America | Not disclosed | United States | |
| Isomorphic Labs | Generative Small-Molecule Design | May 2026 | Series B | $2.1B | AI discovery and design of medicines | Europe | Thrive Capital | United Kingdom | |
| Galux | AI Therapeutic Biologics / Protein Design | May 2026 | Growth Equity | ~$1.4M | AI-driven protein and antibody design | Asia-Pacific | Not disclosed | South Korea | |
| Genesis Molecular AI | Generative Small-Molecule Design | May 2026 | Unknown | $40M | AI-designed small-molecule therapeutics | North America | Incyte | United States | |
| Stoked Bio | AI Hit Discovery & Lead Generation | May 2026 | Seed | Undisclosed | Therapies targeting drug-resistant diseases | North America | Not disclosed | Canada | |
| ALP Bio | Preclinical Predictive AI & Autonomous DMTA | April 2026 | Seed | $2.2M | AI drug discovery for protein therapeutics | Europe | 42CAP | Switzerland | |
| Aureka Biotechnologies | Generative Small-Molecule Design | April 2026 | Series A | $35M | AI foundation models for therapeutics | North America | HongShan | United States | |
| Fathom Therapeutics | Generative Small-Molecule Design | April 2026 | Series A | $47M | AI and physics-based molecule design | North America | Sutter Hill Ventures | United States | |
| 10x Science | Preclinical Predictive AI & Autonomous DMTA | April 2026 | Seed | $4.8M | AI platform for drug discovery | North America | Initialized Capital | United States | |
| Biossil | AI Repurposing / Indication Selection | April 2026 | Unknown | $43M | Uses AI to identify and redevelop previously abandoned drug candidates for new therapeutic applications. | North America | Founders Fund, OpenAI | Canada | |
| Helical | AI Target & Causal Biology Discovery | April 2026 | Seed | $10M | Biological AI models for drug research | Europe | redalpine | United Kingdom | |
| Syneron Bio | AI Hit Discovery & Lead Generation | March 2026 | Series B | $150M | AI-powered macrocyclic peptide drug discovery | Asia-Pacific | Decheng Capital, CDH VGC | China | |
| RyboDyn | AI Target & Causal Biology Discovery | March 2026 | Seed | $10M | AI-designed ribosome-targeting therapeutics | North America | Not disclosed | United States | |
| Earendil Labs | AI Therapeutic Biologics / Protein Design | March 2026 | Unknown | $787M | AI-driven antibody and biologics development | North America | Not disclosed | United States | |
| Congruence Therapeutics | AI Hit Discovery & Lead Generation | March 2026 | Unknown | $40M | Computational therapies for protein misfolding | North America | Dimension, OrbiMed | Canada | |
| Peak Perform Innova | AI Hit Discovery & Lead Generation | March 2026 | Seed | Undisclosed | AI drug discovery for complex diseases | Asia-Pacific | Huagai Capital, BioTrack Capital | China | |
| Ternary Therapeutics | Generative Small-Molecule Design | March 2026 | Seed | ~$4.8M | AI-designed molecular glue therapeutics | Europe | Daphni | United Kingdom | |
| Numerion Labs | AI Hit Discovery & Lead Generation | March 2026 | Series D+ | $20M | AI-powered small molecule drug discovery | North America | Not disclosed | United States | |
| Antiverse | AI Therapeutic Biologics / Protein Design | March 2026 | Series A | $9.3M | AI designed therapeutic antibodies for drug targets | Europe | Soulmates Ventures | United Kingdom | |
| Tamarind Bio | AI Therapeutic Biologics / Protein Design | February 2026 | Series A | $12M | Cloud computational tools for biotech research | North America | Dimension Capital | United States | |
| Turbine | Preclinical Predictive AI & Autonomous DMTA | February 2026 | Series B | $25M | Virtual cell simulation for drug discovery | Europe | Interactive Venture Partners | Hungary | |
| Peptris Technologies | Generative Small-Molecule Design | February 2026 | Series A | $7.7M | AI peptide drug discovery platform | Asia-Pacific | IAN Alpha Fund, Speciale Invest | India | |
| Pharmacelera | AI Hit Discovery & Lead Generation | February 2026 | Series A | $7.1M | AI molecular design for drug discovery | Europe | Heran Partners | Spain | |
| Chemify | Preclinical Predictive AI & Autonomous DMTA | February 2026 | Series B | ~$500K | Automated AI-powered molecular synthesis | Europe | Zeon Corporation | United Kingdom | |
| Sable Bio | Preclinical Predictive AI & Autonomous DMTA | February 2026 | Seed | $3.8M | AI drug discovery for therapeutics | Europe | MMC Ventures | United Kingdom | |
| Galux | AI Therapeutic Biologics / Protein Design | February 2026 | Series B | $31M | AI-driven protein and antibody design | Asia-Pacific | Yuanta Investment | South Korea | |
| LabGenius | AI Therapeutic Biologics / Protein Design | February 2026 | Series B | Undisclosed | AI-directed therapeutic antibody engineering | Europe | Not disclosed | United Kingdom | |
| Proxima | Generative Small-Molecule Design | January 2026 | Seed | $80M | Designs protein-interaction targeting medicines | North America | DCVC | United States | |
| Converge Bio | AI Hit Discovery & Lead Generation | January 2026 | Series A | $25M | AI platform for drug discovery | Middle East | Bessemer Venture Partners | Israel | |
| Zenitar | AI Lead Optimization & Medicinal Chemistry | January 2026 | Series C | Undisclosed | AI-guided clinical-stage drug discovery | Asia-Pacific | Temasek, Qiming Venture Partners | China | |
| Boltz PBC | Generative Small-Molecule Design | January 2026 | Seed | $28M | AI models for biomolecular design | North America | Amplify Partners, Andreessen Horowitz, Zetta Venture Partners | United States | |
| Topos Bio | Generative Small-Molecule Design | January 2026 | Seed | $10M | AI models for drug discovery | North America | Boldstart Ventures, Threshold Ventures | United States | |
| Soley Therapeutics | AI Phenotypic & Functional Screening | January 2026 | Series C | $200M | AI-powered cellular stress drug discovery | North America | Surveyor Capital | United States | |
| Syneron Bio | AI Hit Discovery & Lead Generation | December 2025 | Series A | Undisclosed | AI-powered macrocyclic peptide drug discovery | Asia-Pacific | AstraZeneca, AZ-CICC Healthcare Investment Fund | China | |
| Phil Rivers Technology | AI Target & Causal Biology Discovery | December 2025 | Series A | $14M | Disease simulation for drug discovery | Asia-Pacific | CAS Investment | China | |
| Chai Discovery | AI Therapeutic Biologics / Protein Design | December 2025 | Series B | $130M | AI foundation models for molecular design | North America | General Catalyst, Oak HC/FT | United States | |
| Chemify | Preclinical Predictive AI & Autonomous DMTA | December 2025 | Series B | $1.4M | Automated AI-powered molecular synthesis | Europe | Not disclosed | United Kingdom | |
| PsiThera | AI Hit Discovery & Lead Generation | December 2025 | Series A | $48M | AI-designed medicines for difficult protein targets | North America | Samsara Biocapital, Lightstone Ventures | United States | |
| Relation Therapeutics | AI Target & Causal Biology Discovery | December 2025 | Seed | $26M | Discovers targets using multimodal biology | Europe | DCVC, NVIDIA, Magnetic Ventures | United Kingdom | |
| ChemLex | AI Hit Discovery & Lead Generation | December 2025 | Series A | $45M | AI chemistry platform for drug discovery | Asia-Pacific | Granite Asia | Singapore | |
| TRIANA Biomedicines | AI Hit Discovery & Lead Generation | December 2025 | Series B | $120M | Molecular glue targeted protein degradation | North America | Ascenta Capital, Bessemer Venture Partners | United States | |
| immunitoAI | AI Therapeutic Biologics / Protein Design | November 2025 | Series A | $6.1M | AI designed antibodies for therapeutic discovery | Asia-Pacific | Ashish Kacholia | India | |
| Profluent | Generative Small-Molecule Design | November 2025 | Series B | $106M | Designs proteins using generative AI | North America | Altimeter Capital, Bezos Expeditions | United States | |
| AI Proteins | AI Therapeutic Biologics / Protein Design | November 2025 | Series A | $42M | Designed miniprotein medicines for therapeutic targets | North America | Mission BioCapital, Santé Ventures | United States | |
| Tandem AI | AI Hit Discovery & Lead Generation | November 2025 | Series A | $22M | Integrated AI drug discovery services | North America | VCapital, KHK Fund | United States | |
| Scripta Therapeutics | AI Target & Causal Biology Discovery | November 2025 | Seed | $12M | AI drug discovery for gene regulation | Europe | Oxford Science Enterprises, Apollo Health Ventures | United Kingdom | |
| Arpeggio Biosciences | AI Target & Causal Biology Discovery | November 2025 | Unknown | $20M | Transcriptomics platform for drug discovery | North America | Not disclosed | United States | |
| Iambic Therapeutics | Generative Small-Molecule Design | November 2025 | Series B | $100M+ | AI-driven clinical drug development | North America | Not disclosed | United States | |
| Aureka Biotechnologies | Generative Small-Molecule Design | November 2025 | Series A | $23M | AI foundation models for therapeutics | North America | 5Y Capital, Qiming Venture Partners | United States | |
| LifeMine Therapeutics | AI Hit Discovery & Lead Generation | November 2025 | Series D+ | $75M | Fungal-derived therapeutic drug discovery | North America | Not disclosed | United States | |
| Expedition Medicines | Generative Small-Molecule Design | October 2025 | Series A | $50M | AI-designed small molecule medicines | North America | Flagship Pioneering | United States | |
| NewLimit | AI Target & Causal Biology Discovery | October 2025 | Growth Equity | $45M | Develops epigenetic rejuvenation medicines | North America | Eli Lilly and Company | United States | |
| Peptilogics | AI Therapeutic Biologics / Protein Design | October 2025 | Series B | $78M | Engineers antimicrobial peptide therapeutics | North America | Presight Capital, Thiel Bio, Founders Fund | United States | |
| Bexorg | Preclinical Predictive AI & Autonomous DMTA | October 2025 | Series A | $23M | AI brain drug discovery platform | North America | Engine Ventures | United States | |
| Meta-Flux | Preclinical Predictive AI & Autonomous DMTA | October 2025 | Seed | $2M | Disease simulation for drug target discovery | Europe | Not disclosed | Ireland | |
| Tres Alchemix | Preclinical Predictive AI & Autonomous DMTA | September 2025 | Series A | $4.4M | AI-designed small molecule drug discovery | Asia-Pacific | DNX Ventures | Japan | |
| Manas AI | Generative Small-Molecule Design | September 2025 | Seed | $26M | AI-powered oncology drug discovery | North America | Not disclosed | United States | |
| DaltonTx | AI Lead Optimization & Medicinal Chemistry | September 2025 | Seed | $5.1M | AI decision engine for drug discovery | Europe | redalpine, IQ Capital Partners | United Kingdom | |
| Odyssey Therapeutics | AI Lead Optimization & Medicinal Chemistry | September 2025 | Series D+ | $213M | Develops precision autoimmune disease treatments | North America | Not disclosed | United States | |
| Alchemab Therapeutics | AI Therapeutic Biologics / Protein Design | September 2025 | Series A | $32M | AI-enabled protective antibody drug discovery | Europe | Not disclosed | United Kingdom | |
| Enveda Biosciences | AI Hit Discovery & Lead Generation | September 2025 | Series D+ | $150M | AI discovery of nature-derived medicines | North America | Premji Invest | United States | |
| Congruence Therapeutics | AI Hit Discovery & Lead Generation | September 2025 | Unknown | $32M | Computational therapies for protein misfolding | North America | Not disclosed | Canada | |
| CHARM Therapeutics | Generative Small-Molecule Design | September 2025 | Series B | $80M | AI-designed precision cancer therapeutics | Europe | New Enterprise Associates, SR One | United Kingdom | |
| Chemify | Preclinical Predictive AI & Autonomous DMTA | September 2025 | Series B | $51M+ | Automated AI-powered molecular synthesis | Europe | Wing Venture Capital, Insight Partners | United Kingdom | |
| Therna Biosciences | AI Therapeutic Biologics / Protein Design | August 2025 | Seed | $10M | Computational design of RNA medicines | North America | AIX Ventures, Pear VC, Fusion Fund | United States | |
| Sensorium Therapeutics | AI Hit Discovery & Lead Generation | August 2025 | Series A | $25M | AI-supported neuropsychiatric drug discovery | North America | Not disclosed | United States | |
| Tahoe Therapeutics | Preclinical Predictive AI & Autonomous DMTA | August 2025 | Series A | $30M | AI models trained on cellular data | North America | Amplify Partners | United States | |
| Ribopeutic | AI Target & Causal Biology Discovery | August 2025 | Seed | ~$14M | Uses AI to predict RNA structures and identify druggable RNA targets for small-molecule discovery. | Asia-Pacific | Tasly Capital, Panlin Capital | China | |
| Chai Discovery | AI Therapeutic Biologics / Protein Design | August 2025 | Series A | $70M | AI foundation models for molecular design | North America | Menlo Ventures | United States | |
| Zenitar | AI Lead Optimization & Medicinal Chemistry | August 2025 | Series B | Undisclosed | AI-guided clinical-stage drug discovery | Asia-Pacific | Qiming Venture Partners | China | |
| Synfini | AI Lead Optimization & Medicinal Chemistry | July 2025 | Seed | $8.9M | AI drug discovery and robotic lab | North America | JSL Health Capital | United States | |
| Healx | AI Repurposing / Indication Selection | July 2025 | Series C | $2M | AI-driven rare disease therapeutics | Europe | SCI Ventures | United Kingdom | |
| OutSee | AI Target & Causal Biology Discovery | June 2025 | Seed | $2.3M | AI platform for drug target discovery | Europe | Ahren Innovation Capital | United Kingdom | |
| Insilico Medicine | Generative Small-Molecule Design | June 2025 | Series D+ | $13M | AI-driven drug discovery and development | Asia-Pacific | Value Partners Group, Shanghai Pudong Venture Investment, Shanghai Pudong Development (Group), Wuxi Capital Group, Yixing State-owned Capital Investment Holding Group | Hong Kong | |
| Parallel Bio | Preclinical Predictive AI & Autonomous DMTA | June 2025 | Series A | $21M | Human immune models for drug discovery | North America | AIX Ventures | United States | |
| Kiin Bio | AI Hit Discovery & Lead Generation | June 2025 | Seed | $2.2M | AI designed small molecule therapeutics | Europe | b2venture | United Kingdom | |
| Ternary Therapeutics | Generative Small-Molecule Design | June 2025 | Seed | Undisclosed | AI-designed molecular glue therapeutics | Europe | Not disclosed | United Kingdom | |
| Vivodyne | Preclinical Predictive AI & Autonomous DMTA | May 2025 | Series A | $40M | Lab-grown human tissues for drug testing | North America | Khosla Ventures | United States | |
| ProteinQure | AI Therapeutic Biologics / Protein Design | May 2025 | Series A | $11M | AI designed peptide drugs for cancer | North America | Tom Williams / Heron Rock Fund | Canada | |
| iSiP | Generative Small-Molecule Design | May 2025 | Series A | ~$4.5M | AI drug discovery for novel compounds | Asia-Pacific | DNX Ventures | Japan | |
| Pathos AI | AI Target & Causal Biology Discovery | May 2025 | Series D+ | $365M | Uses agentic AI and human disease data to identify therapeutic assets, test disease-biology hypotheses and guide oncology drug development. | North America | Not disclosed | United States | |
| Inductive Bio | AI Lead Optimization & Medicinal Chemistry | May 2025 | Series A | $25M | AI drug discovery for small molecules | North America | Obvious Ventures | United States | |
| NewLimit | AI Target & Causal Biology Discovery | May 2025 | Series B | $130M | Develops epigenetic rejuvenation medicines | North America | Kleiner Perkins | United States | |
| Divamics | AI Lead Optimization & Medicinal Chemistry | May 2025 | Series A | Undisclosed | AI drug discovery and molecular design | Asia-Pacific | YuanBio Venture Capital | China | |
| Denovo Sciences | Generative Small-Molecule Design | May 2025 | Unknown | $1M | AI-designed small molecule drug candidates | Europe | Alchemist Doha | Armenia | |
| AMPLY Discovery | AI Target & Causal Biology Discovery | May 2025 | Seed | $1.8M | AI-designed therapeutics and antimicrobial discovery | Europe | Twin Path Ventures | United Kingdom | |
| Meddenovo Drug Design | Generative Small-Molecule Design | May 2025 | Seed | $450K | AI protein and drug design platform | Europe | Not disclosed | France | |
| Xellar Biosystems | Preclinical Predictive AI & Autonomous DMTA | April 2025 | Unknown | Undisclosed | AI-powered human cellular modeling | North America | XtalPi | United States | |
| Etiome | AI Target & Causal Biology Discovery | April 2025 | Unknown | $50M | AI drug discovery for preventive medicines | North America | Flagship Pioneering | United States | |
| Araceli Biosciences | AI Phenotypic & Functional Screening | April 2025 | Seed | $7.2M | Provides AI-assisted high-content cellular imaging and phenotypic analysis for preclinical drug screening. | North America | Not disclosed | United States | |
| BigHat Biosciences | AI Therapeutic Biologics / Protein Design | April 2025 | Series B | $44M | AI-driven antibody and protein engineering | North America | Not disclosed | United States | |
| Isomorphic Labs | Generative Small-Molecule Design | March 2025 | Series A | $600M | AI discovery and design of medicines | Europe | Thrive Capital | United Kingdom | |
| Olio Labs | AI Lead Optimization & Medicinal Chemistry | March 2025 | Seed | $4.5M | AI-designed multi-protein therapeutic drugs | North America | Boom Capital, Overwater Ventures | United States | |
| Arpeggio Biosciences | AI Target & Causal Biology Discovery | March 2025 | Unknown | $4M | Transcriptomics platform for drug discovery | North America | Not disclosed | United States | |
| Arbor Biotechnologies | AI Therapeutic Biologics / Protein Design | March 2025 | Series C | $74M | AI-assisted precision gene editing therapies | North America | ARCH Venture Partners, TCGX | United States | |
| Insilico Medicine | Generative Small-Molecule Design | March 2025 | Series D+ | $110M | AI-driven drug discovery and development | Asia-Pacific | Value Partners Group | Hong Kong | |
| Valo Health | AI Target & Causal Biology Discovery | March 2025 | Unknown | $21M | AI-driven computational drug development | North America | Indaco Venture Partners, CDP Venture Capital SGR | United States | |
| Alivexis | AI Lead Optimization & Medicinal Chemistry | March 2025 | Series D+ | $680K | Small-molecule therapies for difficult targets | Asia-Pacific | Not disclosed | Japan | |
| Eikon Therapeutics | AI Phenotypic & Functional Screening | February 2025 | Series D+ | $351M | Computational imaging-driven drug discovery | North America | Not disclosed | United States | |
| InVirtuoLabs | Generative Small-Molecule Design | February 2025 | Seed | $3.1M | AI drug discovery and molecular simulation | Europe | Not disclosed | Switzerland | |
| Achira | Preclinical Predictive AI & Autonomous DMTA | February 2025 | Seed | $33M | AI drug discovery for protein interactions | North America | Dimension | United States | |
| CircNova | AI Therapeutic Biologics / Protein Design | February 2025 | Seed | $3.3M | Generative design platform for RNA therapeutics | North America | South Loop Ventures | United States | |
| Variational AI | AI Hit Discovery & Lead Generation | February 2025 | Seed | $5.5M | AI-designed small molecule drug candidates | North America | Nimbus Synergies | Canada | |
| Latent Labs | AI Therapeutic Biologics / Protein Design | February 2025 | Series A | $40M | Generative AI protein design | Europe | Radical Ventures, Sofinnova Partners | United Kingdom | |
| Latent Labs | AI Therapeutic Biologics / Protein Design | February 2025 | Seed | $10M | Generative AI protein design | Europe | Pillar VC, Kindred Capital | United Kingdom | |
| Ordaos Bio | AI Therapeutic Biologics / Protein Design | February 2025 | Seed | $338K | Generative protein design for therapeutic discovery | North America | Not disclosed | United States | |
| Manas AI | Generative Small-Molecule Design | January 2025 | Seed | $25M | AI-powered oncology drug discovery | North America | General Catalyst, Reid Hoffman | United States | |
| RyboDyn | AI Target & Causal Biology Discovery | January 2025 | Seed | $4M | AI-designed ribosome-targeting therapeutics | North America | Genedant Capital, SeaX Ventures | United States | |
| Graph Therapeutics | AI Target & Causal Biology Discovery | January 2025 | Seed | $3.1M | AI drug discovery for inflammatory diseases | Europe | Squareone, Merantix Capital | Austria | |
| Pepticom | AI Therapeutic Biologics / Protein Design | January 2025 | Series A | $6.6M | AI peptide candidate discovery for therapeutics | Middle East | Japan Israel High Tech Ventures 2 LP | Israel | |
| Alivexis | AI Lead Optimization & Medicinal Chemistry | January 2025 | Series D+ | $5.4M | Small-molecule therapies for difficult targets | Asia-Pacific | JIC Venture Growth Investments | Japan | |
| Orbis Medicines | Generative Small-Molecule Design | January 2025 | Series A | $99M | AI designed oral macrocyclic drug candidates | Europe | New Enterprise Associates | Denmark | |
| DeepLife | AI Target & Causal Biology Discovery | December 2024 | Series A | $10M | Cell digital twins for drug discovery | Europe | YZR Capital, Relyens Innovation Santé | France | |
| Aqemia | Generative Small-Molecule Design | December 2024 | Series A | $38M | Physics-based generative AI drug discovery | Europe | Cathay Capital | France | |
| deepmirror | AI Lead Optimization & Medicinal Chemistry | December 2024 | Seed | $2.4M | Foundation models for molecular drug design | Europe | Twin Path Ventures | United Kingdom | |
| Orakl Oncology | AI Phenotypic & Functional Screening | December 2024 | Seed | Undisclosed | Combines AI with patient-derived tumor organoid screens to select preclinical oncology drugs and uncover biological co-targets. | Europe | Singular | France | |
| Cradle | AI Therapeutic Biologics / Protein Design | November 2024 | Series B | $73M | AI platform for protein engineering | Europe | IVP | Netherlands | |
| Enveda Biosciences | AI Hit Discovery & Lead Generation | November 2024 | Series C | $130M | AI discovery of nature-derived medicines | North America | Kinnevik, FPV | United States | |
| Aizen Therapeutics | AI Therapeutic Biologics / Protein Design | November 2024 | Seed | $13M | AI designed therapeutic peptides for immunology | North America | Madrona Venture Group | United States | |
| Modulo Bio | AI Target & Causal Biology Discovery | November 2024 | Unknown | $5.8M | Neuroimmune drug discovery platform | North America | Not disclosed | United States | |
| Converge Bio | AI Hit Discovery & Lead Generation | November 2024 | Seed | $5.5M | AI platform for drug discovery | Middle East | TLV Partners | Israel | |
| SRTD biotech | AI Therapeutic Biologics / Protein Design | November 2024 | Seed | Undisclosed | Uses AI-driven RNA-marker identification and construct design to generate cell-selective mRNA therapeutics. | Europe | High-Tech Gründerfonds | Germany | |
| AIMEDORIG | Generative Small-Molecule Design | November 2024 | Seed | Undisclosed | AI-designed small molecule drug candidates | Asia-Pacific | Not disclosed | China | |
| AI|ffinity s.r.o | AI Hit Discovery & Lead Generation | November 2024 | Seed | $462K | AI drug discovery for small molecules | Europe | Garage Angels | Czech Republic | |
| Ternary Therapeutics | Generative Small-Molecule Design | November 2024 | Seed | Undisclosed | AI-designed molecular glue therapeutics | Europe | Not disclosed | United Kingdom | |
| Archon Biosciences | AI Therapeutic Biologics / Protein Design | October 2024 | Seed | $20M | Computationally designed therapeutic antibody nanostructures | North America | Madrona Ventures | United States | |
| Transition Bio | AI Lead Optimization & Medicinal Chemistry | October 2024 | Unknown | $13M | Biomolecular condensate drug discovery platform | North America | Not disclosed | United States | |
| Pathos AI | AI Target & Causal Biology Discovery | October 2024 | Series C | $62M | Uses agentic AI and human disease data to identify therapeutic assets, test disease-biology hypotheses and guide oncology drug development. | North America | New Enterprise Associates | United States | |
| Fable Therapeutics | AI Therapeutic Biologics / Protein Design | October 2024 | Seed | $10M | AI-designed metabolic disease biologics | North America | Versant Ventures, DCVC Bio | United States | |
| Terray Therapeutics | AI Lead Optimization & Medicinal Chemistry | October 2024 | Series B | $120M | AI-driven small molecule drug discovery | North America | Bedford Ridge Capital, NVIDIA | United States | |
| AIGEN Sciences | AI Lead Optimization & Medicinal Chemistry | October 2024 | Series A | $8.8M | AI drug discovery for cancer therapeutics | Asia-Pacific | Not disclosed | South Korea | |
| Shift Bioscience | AI Target & Causal Biology Discovery | October 2024 | Seed | $16M | AI-based therapeutic target discovery for aging | Europe | BGF | United Kingdom | |
| Antiverse | AI Therapeutic Biologics / Protein Design | October 2024 | Seed | $4.6M | AI designed therapeutic antibodies for drug targets | Europe | i&i Biotech Fund I, Kadmos Capital | United Kingdom | |
| Basecamp Research | AI Therapeutic Biologics / Protein Design | October 2024 | Series B | $60M | Biodiversity-trained AI protein design models | Europe | Singular | United Kingdom | |
| Arda Therapeutics | AI Target & Causal Biology Discovery | October 2024 | Series A | $43M | Cell-depleting therapies for chronic diseases | North America | a16z Bio + Health | United States | |
| Integrated Biosciences | AI Hit Discovery & Lead Generation | October 2024 | Seed | $17M | AI discovery of drugs targeting aging | North America | Sutter Hill Ventures | United States | |
| Fable Therapeutics | AI Therapeutic Biologics / Protein Design | October 2024 | Series A | $44M | AI-designed metabolic disease biologics | North America | Versant Ventures, DCVC Bio | United States | |
| Model Medicines | Generative Small-Molecule Design | September 2024 | Unknown | $15M | AI-designed drugs for infectious diseases | North America | Not disclosed | United States | |
| Generate:Biomedicines | AI Therapeutic Biologics / Protein Design | September 2024 | Growth Equity | $15M | Generative AI-designed protein therapeutics | North America | Not disclosed | United States | |
| CardiaTec Biosciences | AI Target & Causal Biology Discovery | September 2024 | Seed | $6.5M | AI drug discovery for cardiovascular diseases | Europe | Montage Ventures | United Kingdom | |
| Superluminal Medicines | Generative Small-Molecule Design | September 2024 | Series A | $120M | AI-designed GPCR-targeted medicines | North America | RA Capital Management | United States | |
| Chai Discovery | AI Therapeutic Biologics / Protein Design | September 2024 | Seed | ~$30M | AI foundation models for molecular design | North America | Thrive Capital, OpenAI, Dimension Capital | United States | |
| BioAge Labs | AI Target & Causal Biology Discovery | September 2024 | Unknown | $11M | AI-driven aging and metabolic therapeutics | North America | Not disclosed | United States | |
| Noetik | AI Target & Causal Biology Discovery | August 2024 | Series A | $40M | Builds AI cancer biology models | North America | Polaris Partners | United States | |
| Ordaos Bio | AI Therapeutic Biologics / Protein Design | August 2024 | Seed | $3.1M | Generative protein design for therapeutic discovery | North America | Not disclosed | United States | |
| Talus Bioscience | AI Hit Discovery & Lead Generation | August 2024 | Seed | $11M | AI drug discovery for transcription factor targets | North America | Two Bear Capital | United States | |
| Outpace Bio | AI Therapeutic Biologics / Protein Design | August 2024 | Series B | $144M | Engineers programmable solid-tumor cell therapies | North America | RA Capital Management | United States | |
| Healx | AI Repurposing / Indication Selection | August 2024 | Series C | $47M | AI-driven rare disease therapeutics | Europe | R42 Group, Atomico | United Kingdom | |
| Meddenovo Drug Design | Generative Small-Molecule Design | July 2024 | Seed | Undisclosed | AI protein and drug design platform | Europe | ACT Venture Partners | France | |
| ReviR Therapeutics | AI Hit Discovery & Lead Generation | July 2024 | Series A | $30M | Develops AI-designed RNA-modulating medicines | North America | Lapam Capital | United States | |
| Brenig Therapeutics | Generative Small-Molecule Design | July 2024 | Series A | $65M | AI-designed neurodegenerative disease therapeutics | North America | New Enterprise Associates | United States | |
| CytoReason | AI Target & Causal Biology Discovery | July 2024 | Series B | $80M | AI models of human disease | Middle East | Not disclosed | Israel | |
| Xellar Biosystems | Preclinical Predictive AI & Autonomous DMTA | July 2024 | Seed | ~$14M | AI-powered human cellular modeling | North America | TriApex Group | United States | |
| Helical | AI Target & Causal Biology Discovery | June 2024 | Seed | $2.4M | Biological AI models for drug research | Europe | Not disclosed | United Kingdom | |
| Iambic Therapeutics | Generative Small-Molecule Design | June 2024 | Series B | $50M | AI-driven clinical drug development | North America | Mubadala Capital, Exor Ventures | United States | |
| Ability Biologics | AI Therapeutic Biologics / Protein Design | June 2024 | Seed | $6M | AI-designed multispecific antibody therapeutics | North America | Amplitude Ventures | Canada | |
| Enveda Biosciences | AI Hit Discovery & Lead Generation | June 2024 | Series B | $55M | AI discovery of nature-derived medicines | North America | Not disclosed | United States | |
| Envisagenics | AI Target & Causal Biology Discovery | June 2024 | Series B | $25M | RNA splicing drug discovery software | North America | Not disclosed | United States | |
| Vilya | Generative Small-Molecule Design | June 2024 | Series A | $21M | Computational design of macrocyclic medicines | North America | ARCH Venture Partners | United States | |
| LabGenius | AI Therapeutic Biologics / Protein Design | May 2024 | Series B | $45M | AI-directed therapeutic antibody engineering | Europe | M Ventures | United Kingdom | |
| Nabla Bio | AI Therapeutic Biologics / Protein Design | May 2024 | Series A | $26M | Generative AI antibody design | North America | Radical Ventures | United States | |
| Prologue Medicines | AI Hit Discovery & Lead Generation | May 2024 | Series A | $50M | Discovers therapies from viral proteins | North America | Flagship Pioneering | United States | |
| Sortera Bio | AI Hit Discovery & Lead Generation | May 2024 | Seed | $9.6M | AI-designed biologics for difficult drug targets | Europe | Cambridge Innovation Capital | United Kingdom | |
| Transcripta Bio | AI Repurposing / Indication Selection | April 2024 | Unknown | $10M | AI-guided drug discovery platform | North America | Not disclosed | United States | |
| Xaira Therapeutics | AI Therapeutic Biologics / Protein Design | April 2024 | Series A | $1.0B+ | AI-designed medicines and biological models | North America | ARCH Venture Partners, Foresite Capital | United States | |
| DeepCure | Generative Small-Molecule Design | April 2024 | Series A | $25M | AI-designed small-molecule drug discovery | North America | IAG Capital Partners | United States | |
| Leash Biosciences | AI Hit Discovery & Lead Generation | April 2024 | Seed | $9.3M | Machine learning for protein drug discovery | North America | Springtide Ventures | United States | |
| Profluent | Generative Small-Molecule Design | March 2024 | Series A | $35M | Designs proteins using generative AI | North America | Spark Capital | United States | |
| Relation Therapeutics | AI Target & Causal Biology Discovery | March 2024 | Seed | $35M | Discovers targets using multimodal biology | Europe | DCVC, NVIDIA | United Kingdom | |
| SOM Biotech | AI Repurposing / Indication Selection | March 2024 | Unknown | ~$6M | AI-assisted drug repurposing development | Europe | Not disclosed | Spain | |
| Orbis Medicines | Generative Small-Molecule Design | February 2024 | Seed | $29M | AI designed oral macrocyclic drug candidates | Europe | Novo Holdings, Forbion | Denmark | |
| Frontier Medicines | AI Hit Discovery & Lead Generation | February 2024 | Series C | $80M | AI-enabled precision oncology drug discovery | North America | Deerfield Management, Droia Ventures | United States | |
| Insamo | Generative Small-Molecule Design | February 2024 | Seed | $12M | AI-designed cyclic peptide medicines | North America | Playground Global | United States | |
| BioAge Labs | AI Target & Causal Biology Discovery | February 2024 | Series D+ | $170M | AI-driven aging and metabolic therapeutics | North America | Sofinnova Investments | United States | |
| Sable Bio | Preclinical Predictive AI & Autonomous DMTA | February 2024 | Seed | ~$1.9M | AI drug discovery for therapeutics | Europe | Episode 1 Ventures | United Kingdom | |
| Aqemia | Generative Small-Molecule Design | January 2024 | Series A | $32M | Physics-based generative AI drug discovery | Europe | Wendel Growth | France | |
| Athos Therapeutics | AI Target & Causal Biology Discovery | January 2024 | Unknown | $7.6M | AI-powered precision inflammatory disease treatments | North America | Not disclosed | United States | |
| Moonwalk Biosciences | AI Target & Causal Biology Discovery | January 2024 | Series A | $57M | Epigenetic and RNAi therapeutic discovery | North America | Alpha Wave Global | United States | |
| Biossil | AI Repurposing / Indication Selection | 2024 | Series A | $22M | Uses AI to identify and redevelop previously abandoned drug candidates for new therapeutic applications. | North America | Founders Fund | Canada |

In our research about AI drug discovery, we turn what is vague and complex into simple, useful visuals. Market maps like this one show you at a glance where every startup stands.
Is AI drug discovery really attracting billions, or just a few huge checks?
AI drug discovery has attracted billions, but a few enormous deals account for most of the disclosed money.
We tracked 226 financings involving 164 companies and at least $14.1B of announced capital. Take out rounds above $50M and the total drops to at least $2.8B. Remove rounds above $100M and it is at least $4.5B. That still leaves a busy market, just a much smaller one than the headlines suggest.
Consider the financing behind three different ambitions. Isomorphic Labs raised $2.1B in a Series B in May 2026 to advance its AI drug-design engine and internal therapeutic programs. Xaira Therapeutics launched with a $1.0B+ Series A in April 2024 to combine biological models with drug development. Earendil Labs announced $787M across several financing rounds in March 2026 for AI-driven biologics development. Those checks pay for researchers, labs and drug candidates that may take years to reach patients.
The big investors are paying for years of experiments and drug testing, not a standard software launch. Most AI drug discovery companies have to work with checks far smaller than those received by the standout developers.
How much does an AI drug discovery startup normally raise?
The typical AI drug discovery financing is $25M, far below the billion-dollar rounds that make headlines.
We found a public amount for 208 deals, and another 18 did not disclose their size. A headline round is a terrible benchmark for a founder planning their first experiments.
The spread is enormous. Rounds under $5M account for 34 disclosed-size deals, or 16%, with $90M in combined capital. The $5M to under $20M band contains 58 deals and $595M. Another 58 deals fall between $20M and under $50M, bringing at least $1.8B. That middle range says much more about daily fundraising than the billion-dollar announcements.
The companies are paying for very different work. Venomics AI's $2.7M Seed in November 2026 supports an AI and experimental peptide-discovery approach. Atlas Bio's $10M Seed in October 2026 backs a human-transcriptomics foundation-model effort. Undecimal Bio's $18M Seed in October 2026 joins prediction with biological screening for lead design. All sit inside the same market, but their immediate technical and laboratory requirements differ.
A new founder should budget for the experiments needed to prove the idea, rather than assume a blockbuster biotech launch is the price of entry.
Are $100M rounds becoming normal in AI drug discovery?
No. AI drug discovery startups do raise $100M or more, but those checks are still rare.
We recorded 31 such deals, representing 15% of financings with public amounts, and at least $9.8B in capital. The stricter group of rounds above $100M contains 29 deals, or 13% of all recorded financings, and at least $9.6B.
These large rounds support quite different companies. Chai Discovery raised $400M in a Series C in July 2026 to develop molecular-design technology used by pharmaceutical partners. NewLimit raised $435M in a Series C in June 2026 to advance epigenetic reprogramming medicines toward human testing. Enveda Biosciences raised $311M in a Series D+ round in September 2026 while scaling a platform that identifies drug-like molecules in nature and moving its own therapies through clinical trials.
Each company still has expensive science to carry out after the models produce candidates. Chai must demonstrate experimentally that designed biological molecules behave as intended. NewLimit must test whether its cell-reprogramming approach becomes an effective treatment. Enveda needs clinical studies to determine whether promising compounds benefit patients.
A $100M financing makes news precisely because most startups never raise a check that large.
Why has Isomorphic Labs raised so much money?
Isomorphic Labs has raised more AI drug discovery capital than any other startup we tracked, helped by its drug-design technology and pharmaceutical partnerships.
We recorded $2.7B raised by Isomorphic Labs across 2 rounds, including a $600M Series A in March 2025 and a $2.1B Series B in May 2026. The latter is the largest single deal in this market so far.
Isomorphic Labs has a drug-design engine and working relationships with established drugmakers. Isomorphic announced collaborations with Lilly and Novartis in January 2024, expanded the Novartis partnership in February 2025, and announced a cross-modality collaboration with Johnson & Johnson in January 2026. Its engine is designed to work across targets and molecular types, while its company strategy also includes medicines it owns.
The 2026 financing announcement explicitly linked the new capital to scaling the Isomorphic Labs Drug Design Engine, expanding the business and advancing its drug candidates. The company still has to turn its predictions into molecules that pass laboratory and clinical tests.
Investors clearly believe a company that designs medicines and owns some of them could become very valuable. Whether that belief pays off depends on the drugs, not the size of the funding round.

In our market report about AI drug discovery, we always try to gather several sources and make estimates that make sense, so you can work with solid numbers.
Are investors backing AI drug discovery tools or actual medicines?
Investors back both AI drug discovery tools and companies developing their own medicines, with the biggest checks often going to firms doing both.
A software provider can charge research teams for its tools. A company developing its own medicine also has to pay for the tests that decide whether the drug can reach patients.
Chai Discovery illustrates the platform route. The company develops molecular-design models that pharmaceutical researchers can test against real biological targets. Pathos AI shows the second route: its Foundry technology guides drug-development decisions, but the company also owns or advances an oncology pipeline. Enveda Biosciences connects both sides through PRISM, its nature-derived molecule-discovery system, and medicines it is testing in patients.
Their financing histories show why these models can coexist. Chai Discovery raised $630M across 4 rounds in the window, Pathos AI raised $664M across 3 rounds, and Enveda Biosciences raised $646M across 4 rounds. These are fundraising amounts, not revenue. Investors are willing to fund several routes from an AI model to a medicine.
The trade-off is simple. A platform seller can earn fees earlier, while a startup that owns a drug could make more money if it succeeds. It also has to pay for a long and risky development process.
Why are investors putting so much money into AI-designed proteins?
AI-designed proteins and therapeutic antibodies attract big checks because drugmakers can test the molecules in the lab and potentially turn them into medicines.
We counted 48 deals involving 35 companies and at least $3.9B, with a median round of $30M. These teams want to make working therapeutic molecules, not stop at predicting their shapes.
Major drugmakers are now testing AI antibody design in real collaborations. Chai Discovery has announced work with Lilly, Pfizer, Novartis, GSK, Bristol Myers Squibb, argenx and Roche. These partnerships show that pharmaceutical teams are willing to examine model-designed molecules, although they do not tell us how many will become approved drugs.
Chai Discovery provides a concrete scientific test. In a June 2025 preprint describing Chai-2, its researchers reported a 16% experimental hit rate for fully de novo antibody design. That is a laboratory result, not evidence that these antibodies are approved drugs. Basecamp Research is taking a different approach: its EDEN models draw on biological sequence data and the company says the $140M Series C it announced in September 2026 will advance AI-designed therapeutics, beginning with in vivo cell therapy.
Xaira Therapeutics adds another model, combining AI and experimental biology to develop medicines within the company. Its $1.0B+ Series A in April 2024 shows how far investors may go when they expect to build a drug developer and a technical platform at the same time. Chai's $400M Series C in July 2026 and Basecamp's later financing show that the category also attracts capital after launch.
Pharmaceutical companies can test whether these models produce useful molecules. Manufacturing and clinical trials will show whether those early results lead anywhere.
Are AI-designed small molecules still getting the biggest checks?
AI small-molecule design is among the biggest funding categories, although its lead over protein design is too close to call confidently.
Generative small-molecule design raised at least $4.2B across 45 deals involving 31 companies, with a median round of $32M. Therapeutic biologics and protein design attracted at least $3.9B across 48 deals. The published totals are too close to declare a clear winner.
Isomorphic Labs dominates large small-molecule financings, and other developers are drawing serious checks too. Superluminal Medicines raised $120M in a Series A in September 2024 for AI-designed medicines aimed at difficult GPCR targets. Fathom Therapeutics raised $47M in a Series A in April 2026 for a discovery approach combining AI and physics. These financings support different techniques for designing and improving small molecules, from structure prediction to computational exploration of chemical space.
Drug developers still need small molecules that bind the right targets, behave properly in the body and can be manufactured. Google's AlphaFold 3 work expanded the ability to model molecular interactions. Better computational models can narrow the list of candidates worth making and testing, but do not make laboratory work unnecessary.
The interest makes sense: small-molecule drugs are a core part of pharma research. AI might help scientists find stronger candidates sooner, but it cannot skip the clinical tests.
The table below shows the technology categories and their share of money with a public amount.
| Category | Deals | Disclosed capital | Capital share |
|---|---|---|---|
| Small-molecule design | 45 | $4.2B+ | 30% |
| Therapeutic biologics | 48 | $3.9B+ | 28% |
| Target discovery | 41 | $2.1B+ | 15% |
| Hit discovery | 37 | $1.8B+ | 13% |
| Phenotypic screening | 7 | $621M+ | 4% |
| Preclinical DMTA | 22 | $564M+ | 4% |
| Lead optimization | 17 | $489M+ | 3% |
| Drug repurposing | 9 | $309M | 2% |

Our document detailing everything you need to know about AI drug discovery gets updated several times a month, so you always get the latest view of where things stand.
Can an AI target discovery startup become a real drug developer?
AI target discovery companies can raise enough to develop their own drugs, but finding a target is only the beginning of that work.
We recorded 41 deals involving 29 companies and at least $2.1B, with a median financing of $18M. A drug that targets the wrong biological mechanism can fail even if the chemistry is excellent.
NewLimit raised $435M in a Series C in June 2026 for medicines based on epigenetic reprogramming, after developing an AI-and-genomics discovery system that tests proposed interventions in cells. Pathos AI uses its Foundry system to evaluate disease biology and guide a clinical oncology pipeline. Moonwalk Biosciences raised $70M in a Series B in September 2026 for epigenetic and RNA-targeting discovery programs.
NewLimit studies cellular aging, Pathos uses disease data to guide drug development, and Moonwalk works on gene regulation. Each is trying to find biological openings that other approaches have missed.
NewLimit's June 2026 company announcement said it intended to move its first aging-reprogramming medicine into human studies. Pathos's October announcement described a clinical-stage portfolio, rather than a purely predictive product. Finding the right biological target could unlock a drug program. It still leaves a long road of experiments.
Can AI drug repurposing startups attract serious funding?
AI drug repurposing is a smaller funded business than designing new molecules, yet investors are putting serious money into it.
We tracked 9 deals involving 5 companies and $309M in the AI repurposing and indication-selection category, with a median financing of $22M. These companies look for fresh uses for medicines that someone has already studied, instead of always starting with a new molecule.
Biossil is the prominent example. It raised $153M in a round of undisclosed stage in September 2026, led by the OpenAI Startup Fund, and $43M in a round of undisclosed stage in April 2026. The company uses AI to screen discontinued drug programs for possible new uses, then acquires or licenses selected candidates. Legal adviser Osler confirmed the later financing and its intended support for clinical capacity and candidate acquisitions.
Healx works on a different problem, using AI to pursue therapies for rare diseases. It raised $47M in a Series C in August 2024 and $2M in a Series C in July 2025 in the window. Transcripta Bio, meanwhile, raised $24M in a Series A in July 2026 for an AI-guided approach to drug opportunities. Drug repurposing remains smaller than the main design categories, but it has its own specialist investors and companies.
Earlier research can save time. But a drug abandoned for one disease may fail in another, and the new owner still needs the rights and clinical evidence to justify trying again.
Are robots starting to run AI drug discovery labs?
Yes. Investors are funding AI drug discovery labs that use robots to make and test the molecules their models propose.
The preclinical predictive AI and autonomous design-make-test-analyze category recorded 22 deals involving 16 companies and at least $564M, with a median round of $14M.
Warp Sciences raised $215M in a Series A in October 2026 to build chemistry services that use AI, human chemists and robotics. Its investor Lightspeed described a business meant to automate the repetitive synthesis and testing that follows an initial promising molecule. Chemify applies a related idea through a programmable chemistry system that connects molecular design, synthesis instructions and physical laboratory equipment. It raised $51M+ in a Series B in September 2025. Xellar Biosystems, focused on human cellular models, announced $50M across its Series A and A+ rounds in June 2026.
All these labs try to close the same loop: predict a molecule, make it, test it, then use the result to improve the next prediction. That loop can produce both useful compounds and experimental data competitors may struggle to copy, though the equipment is costly to run.
Chemify says its first dedicated Chemifarm opened in 2025. Warp's announced strategy is to bring more discovery chemistry into automated American facilities. Physical labs need enough paying customers and enough experiments running to justify their cost.

In our report covering the AI drug discovery market, we look at what the winners do differently, so you can learn from the best instead of guessing.
Why are investors putting so much into AI cell screening?
AI-powered cell screening attracts large biotech rounds because its companies need expensive experiments, imaging systems and patient-derived samples.
We recorded 7 deals across 5 companies and at least $621M, with a $30M median round. These teams watch how real cells respond to drugs, rather than depend entirely on predictions from isolated molecules.
Eikon Therapeutics raised $351M in a Series D+ in February 2025 while using advanced imaging and high-performance computing to investigate biology in living cells. Soley Therapeutics raised $200M in a Series C in January 2026 to expand a cell-stress sensing system and advance oncology programs. Orakl Oncology raised $34M in a Series A in November 2026 for a discovery method combining AI with patient-derived tumor organoids.
All three need good experimental data, collected in different ways. Eikon tracks proteins inside living cells, Soley analyzes cellular stress responses, and Orakl tests drug responses in patient-derived models. More sophisticated experiments may improve the relevance of AI predictions, while raising the cost of the equipment, samples and teams needed to generate them.
The FDA's 2025 draft guidance also makes clear that an AI result needs evidence suited to its intended use. Better cell measurements could make drug discovery more reliable, but clinical testing must still show whether the predictions hold up.
Do AI drug discovery startups run out of funding after Series A?
No. AI drug discovery startups face far fewer late-stage rounds, but the companies that progress can still raise large sums.
Seed and Series A deals are common, but far fewer companies reach later stages. Among deals with a named stage, early-stage rounds represented 67% of deal count but 36% of the disclosed capital, while later-stage rounds represented 33% of deal count and 64% of the disclosed capital.
The reason is visible in company trajectories. Chai Discovery moved from a $70M Series A in August 2025 to a $130M Series B in December 2025 and a $400M Series C in July 2026, with each round financing a larger effort around therapeutic molecular design. NewLimit progressed from a $130M Series B in May 2025 to a $435M Series C in June 2026 while advancing its aging-reprogramming programs. Pathos AI raised $365M in a Series D+ in May 2025 and $237M in a Series D+ in October 2026 while expanding its clinical oncology work.
Many startups stay at Seed or Series A during the window. The later checks go to a smaller group with more experiments, stronger partnerships or drug programs to finance.
The undisclosed-stage line includes Earendil Labs' $787M, which the company announced as several financing rounds without naming a stage. The table below shows funding by recorded stage across the full window.
| Stage | Deals | Disclosed capital | Capital share |
|---|---|---|---|
| Series B | 35 | $4.1B+ | 30% |
| Series A | 60 | $3.8B+ | 27% |
| Series D+ | 15 | $2.3B | 16% |
| Series C | 14 | $1.7B+ | 12% |
| Unknown | 24 | $1.4B+ | 10% |
| Seed | 75 | $766M+ | 5% |
| Growth Equity | 3 | $61M | <1% |
Can AI drug discovery startups still launch with a small seed round?
Yes. AI drug discovery startups can launch with relatively small seed checks, provided they tackle a manageable scientific problem.
Seed financings accounted for 75 deals involving 64 companies and at least $766M, with a median of $9.1M. By contrast, the smallest disclosed-size bracket, under $5M across all stages, contained 34 deals.
Venomics AI raised $2.7M in a Seed in November 2026 to combine computational and experimental work around venom-derived therapeutic peptides. In the same month, SRTD biotech recorded a ~$36M Seed for an RNA-focused design workflow. Earlier in January 2026, Proxima raised an $80M Seed to pursue protein-interaction medicines. All are called Seed rounds, but the founders are building very different businesses.
The larger issue is what a new company must prove before pharmaceutical customers and later-stage investors take it seriously. Google DeepMind's AlphaFold tools and NVIDIA's BioNeMo resources make powerful computational capabilities accessible beyond the most richly financed startups. Access to a model, however, is different from having exclusive experimental data, a reproducible hit-finding process or rights to a drug program. A small team can start by proving that its predictions work against a narrow technical problem rather than building a full clinical drug developer immediately.
A Seed label says little about the cost of entry. What counts is whether the money buys enough credible evidence for the next step.
How old are AI drug discovery startups when they raise big rounds?
AI drug discovery startups usually need several years of research before winning very large rounds, although some launch with exceptional backing.
The median company age at a financing was 4 years. For deals above $50M, the median age was 5 years, and for deals under $5M, it was 3 years. Companies with more research behind them tend to receive bigger checks, though age alone does not persuade investors.
The industry is also young. We found that 93% of tracked companies were founded since 2015, 68% since 2020 and 43% since 2022. The newer wave includes firms building biological foundation models, experimental discovery platforms and therapeutic companies. Xaira Therapeutics shows how unusually large starting capital can compress the conventional sequence: its April 2024 launch paired ambitious scientific plans with substantial investor backing. Chai Discovery, in contrast, built a visible progression from its Seed financing to later rounds alongside the release of molecular design tools and pharmaceutical collaborations.
There is no fixed age when a biotech startup becomes fundable. Enveda's natural-products platform needed years of scientific and clinical work before the clinical results it discussed in its September 2026 financing announcement. Warp Sciences entered the market with a substantial robotics-driven laboratory plan before having a comparable long operating history.
Investors look at what the scientists have proved. An experienced founding team can raise a big first check, while others need years of experiments to get there.

In our research about AI drug discovery, we don't want to repeat what boring consulting reports say. Instead, we show you the real and latest market signals that matter.
Do AI drug discovery investors keep backing the same startups?
Most AI drug discovery startups have raised only one round recently, and investors keep returning to a smaller set of companies.
We tracked 114 companies with 1 round, representing 70% of the company base. Another 41 companies raised 2 rounds, or 25%, and 9 companies raised 3 or more, or 5%. In all, 50 companies raised more than once, equivalent to 30% of tracked companies.
That does not mean new companies have stopped getting funded. We identified 45 first financings involving 45 companies, or 20% of the deals, compared with 130 follow-on deals involving 97 companies. First financings brought at least $2.5B, while follow-ons brought at least $10.6B. Another 51 deals stay unclassified, because the sources do not say whether they were first rounds and no earlier equity round is on record. Xaira Therapeutics launched with a $1.0B+ Series A in April 2024, while ALLOX began with a $10M Seed in October 2026. Founders can still get an initial check, but companies already underway absorb more money.
The repeat fundraisers show where investors keep putting their money. Enveda Biosciences raised capital in 4 rounds while building its nature-derived discovery platform and expanding its therapeutic work. Chai Discovery recorded 4 rounds as its molecular models and pharmaceutical relationships developed. Pathos AI recorded 3 rounds as its AI-guided oncology strategy expanded. Repeat rounds show continuing investor support, though they do not prove a drug will succeed.
One recorded deal does not mean a company has never raised elsewhere. It does show how uneven access to new capital has been during this period.
A company selling research software might earn fees before it needs another round. A company developing a drug may need several checks just to reach clinical testing.
Does AI drug discovery funding come in waves or every month?
AI drug discovery startups raise money every month, but a few giant financings make the dollar totals jump suddenly.
In 34 completed months, we recorded no month without a deal. The median completed month had 6 deals and $237M of disclosed capital, and 13 completed months exceeded the median monthly deal count. The deal flow is steady, but the amounts are not.
The busiest months were September 2026 and October 2024, each with 12 deals. The companies differed: October 2024 included financings for Terray Therapeutics, Basecamp Research and Pathos AI, while September 2026 included Enveda Biosciences, Basecamp Research, Anew Labs and BigHat Biosciences. Investors were not all reacting to one technical breakthrough, and activity came from drug design, biological models and companies at different stages.
May 2026, by contrast, carried the highest monthly disclosed sum at $2.2B+, driven by Isomorphic Labs. A month can therefore look extraordinary in dollar terms without being the busiest time for the number of companies financed. That is why a chart of dollars raised can make an ordinary month look like a boom.
Behind the noisy dollar totals, researchers and startups are still raising money regularly. The biggest developers simply change the scale of individual months.
Does the UK really rival the US in AI drug discovery funding?
The United States remains far ahead of the United Kingdom in AI drug discovery financing, even with Britain's exceptionally large rounds.
We tracked 111 US deals across 80 companies and at least $8.8B, representing 49% of deals and 63% of disclosed capital. The United Kingdom recorded 40 deals across 25 companies and at least $3.4B, representing 18% of deals and 24% of disclosed capital.
The typical financing also differs. The US median was $34M, versus $10M for the United Kingdom. Isomorphic Labs' giant rounds make Britain's dollar total look much bigger. Yet the country also has Basecamp Research, which raised $140M in a Series C in September 2026, and CHARM Therapeutics, which raised $80M in a Series B in September 2025. Each has its own science and business model.
The UK has strong scientific infrastructure too. The British government launched the OpenBind project in June 2025 to build a shared body of protein-ligand binding data, addressing a known bottleneck in drug design. The initiative is public research infrastructure, not a financing in our startup totals, but it shows how experimental data and academic resources can help companies develop novel models.
China forms a third significant market, with 19 deals involving 16 companies and at least $629M. The US remains firmly ahead. But British and Chinese companies are attracting substantial backing for different types of drug discovery.
Are big pharmaceutical companies investing in AI drug discovery startups?
Yes. Pharmaceutical companies directly invest in AI drug discovery startups, though they also work with many others through research deals.
A commercial partnership and an equity round are different deals. The total size of a financing also tells us nothing about one investor's individual check.
Bristol Myers Squibb led Pathos AI's $237M Series D+ in October 2026 while entering broader relationships around its Foundry platform and disease research. Incyte led Genesis Molecular AI's $40M round of undisclosed stage in May 2026. Lilly led NewLimit's $45M Growth Equity financing in October 2025, connecting an established drug developer with an epigenetic-reprogramming company. The deal sizes identify the financings as a whole, not the pharmaceutical companies' individual checks.
Other relationships are commercial rather than equity investments. Isomorphic Labs began multi-target research programs with Lilly and Novartis in 2024 and later added Johnson & Johnson. Chai Discovery has announced a series of pharmaceutical research collaborations. Those agreements may provide funding, data, access to expertise or a path to customer adoption, but they do not automatically become venture rounds.
We found 311 distinct investors, most of them outside pharmaceutical companies. Drugmakers are paying to explore the technology and, in selected cases, taking equity stakes too. Neither action proves that the resulting medicines will work.

Learning from others' mistakes is the cheapest lesson there is. In our market report about AI drug discovery, we look at what broke startups before you, so you don't repeat it.
Is NVIDIA an AI drug discovery investor or mainly a supplier?
NVIDIA invests in AI drug discovery startups, but supplying them with computing tools is a much broader part of its business.
We recorded NVIDIA leading 3 financings, whose combined round sizes were $181M. That measures the whole rounds NVIDIA led, not its own checks.
Its technology strategy reaches many more scientific teams. NVIDIA's June 2026 BioNeMo Agent Toolkit announcement added software that helps researchers orchestrate molecular generation, docking, prediction and other scientific computing tasks. Chai Discovery, Basecamp Research and other developers were named among collaborators.
NVIDIA is much more selective about its equity investments. NVIDIA appeared among the lead investors in Relation Therapeutics' $35M Seed in March 2024 and its $26M Seed in December 2025, and as a lead alongside Bedford Ridge Capital in Terray Therapeutics' $120M Series B in October 2024. These examples show how NVIDIA may support companies that can apply biological AI to a genuine discovery workflow, while still selling or enabling computing infrastructure to a much wider ecosystem.
As NVIDIA makes scientific computing tools easier to get, AI drug startups have to offer something more: hard-to-copy data, chemistry expertise or their own drug programs. NVIDIA can supply the tools and still invest in selected customers.
Are AI-designed drugs actually being tested in patients?
Yes. Some AI-designed medicines are now being tested in patients, though clinical trials can still fail.
Insilico Medicine reported dosing the first patient in a Phase III study of rentosertib in September 2026, following earlier studies of its AI-discovered compound for idiopathic pulmonary fibrosis. A Phase III trial is serious progress, but patients still need to benefit.
Enveda Biosciences provides a different example. In its September 2026 company announcement, Enveda said its AI-native PRISM discovery platform had yielded medicines undergoing clinical development, including ENV-294 for inflammatory disease and ENV-308 for metabolic health. It reported early clinical findings and described plans to advance the programs, alongside its $311M Series D+ financing that month. Pathos AI said in October 2026 that its Foundry-guided pipeline included clinical oncology assets, as it raised $237M in a Series D+ and expanded work with Bristol Myers Squibb.
A model can predict a useful molecule, and a lab can confirm an early result. Patient trials test whether it is safe and whether it actually helps people. This is why companies with proprietary medicines may need substantially more capital than a pure model provider. Each stage can expose failures that computing alone cannot exclude.
Regulators are also making the standards clearer. In January 2026, the FDA and European Medicines Agency published good AI practice principles covering model validation, evidence and context of use. Those principles do not certify any particular AI-designed therapy. AI drug discovery has reached the clinic. Whether it produces a strong record of useful medicines is still open.
So, where is AI drug discovery funding really going today?
Most disclosed AI drug discovery funding goes to a small group of huge drug-development bets, even though many more startups raise smaller rounds.
Isomorphic Labs holds the largest individual deal, its $2.1B Series B in May 2026. Founders Fund and New Enterprise Associates each led 4 rounds, more than any other investor. Their activity sits alongside a much wider flow of smaller financings.
The big checks usually pay for research that does not end when a model generates a molecule. Scientists have to make it, test it and often run expensive studies in patients. Startups selling discovery tools can earn fees much earlier, while those keeping rights to their own medicines take on greater risk and potentially greater rewards.
The missing piece is still proof that the technology delivers medicines patients need. Isomorphic Labs has drugmaker partnerships, Chai Discovery has experimental antibody-design results and collaborators, and Enveda has candidates in clinical development. None of those facts guarantees an approved drug. For now, the funding market is well established, and its largest clinical bets still have to prove themselves.
The table below shows what we found.
| Question | Answer |
|---|---|
| Is this market huge without the biggest checks? | Smaller financing tells a much quieter story than headlines. Excluding rounds above $50M leaves at least $2.8B. That changes how we interpret the market's size. |
| Are nine-digit checks now the standard financing size? | No, they dominate capital without becoming routine transactions. Rounds of $100M or more represent 15% of disclosed deals. These checks are still exceptional outcomes for founders. |
| Does Isomorphic Labs represent every AI drug startup? | No, its scale is far from representative today. Isomorphic Labs raised $2.7B across 2 recorded financings. Its unique partnerships help explain the unusually large checks. |
| Do typical financings resemble billion-dollar biotechnology launches? | No, most financings happen at a far smaller scale. The median disclosed deal is $25M. Scientists can start without financing an entire drug pipeline. |
| Which drug design approach draws the biggest money? | Small-molecule and protein design are both major funding destinations. Generative small-molecule design raised at least $4.2B across 45 deals. Close reported totals make a definitive leader premature today. |
| Do investors repeatedly support AI therapeutic protein design? | Yes, this remains an active market for new medicines. Therapeutic biologics and protein design recorded 48 deals. Wet-lab results and pharma relationships help explain investor interest. |
| Is reviving abandoned drug candidates a niche bet? | It is smaller, but meaningful financing has emerged. Drug repurposing recorded 9 deals and $309M in disclosed capital. Biossil demonstrates how neglected compounds can attract investors. |
| Can a new AI drug discovery startup raise? | Yes, founders have secured checks at several sizes. Seed financing accounted for 75 deals across 64 companies. The initial proof required depends on the technology. |
| Does every startup return for a second round? | No, repeat fundraising remains limited to some companies. Only 50 companies raised money more than once here. That divides continuing investors' favorites from one-time recipients. |
| Has Britain overtaken America in drug discovery capital? | No, American funding remains far larger. The United States raised at least $8.8B across 111 deals. Britain still hosts an exceptionally large drug-design developer. |
| Do big financings prove AI-designed drugs will work? | No, investment is not clinical proof of efficacy. The market includes 226 deals across 164 startups. Patient studies must ultimately validate the promised medicines. |

If you build or invest in the AI drug discovery market, you need to know which business models pay off now and which ones are fading. That's why our report covering it has a whole section on it.
Our methodology
Our data runs through November 13, 2026. We cover financings announced from January 1, 2024 through November 13, 2026, rather than presenting lifetime funding histories for every company. The deals list includes equity financings of private companies at or above $300K; debt, grants, loans, unconverted convertibles, SAFEs and public offerings are excluded.
We define AI in drug discovery as companies whose repeatable AI-led processes materially identify, generate, design, optimize or preclinically select therapeutic targets and drug candidates. This includes target biology, phenotypic screening, therapeutic protein and RNA design, molecular generation and lead optimization, drug repurposing, and preclinical prediction with automated laboratories. We include companies near category boundaries when a substantive preclinical discovery product is evidenced, rather than excluding them arbitrarily; diagnostic-only, clinical operations, manufacturing-only and unrelated general-purpose AI businesses do not qualify.
Every company counted is a startup under our definition: an independent technology-led business founded in 2000 or later and built for rapid growth, with venture, angel, founder or eligible other support. Companies that listed within the preceding 5 years or were acquired within the preceding 3 years remain eligible in the historical window when applicable. We count each actual financing once, merge duplicated reports of the same announcement and identify companies at the entity level so changes in names or related businesses do not inflate deal counts.
We count undisclosed financings in deal totals but not capital sums, which is why some capital amounts are minimums and use a plus sign. We assign the stage according to the announced round, treating Seed, Series A and Series B separately from Series C, Series D+, Growth Equity and rounds whose stage is unknown. When we compare early and later stages, we use only deals with a named stage. We attribute countries and regions to company headquarters and classify companies into our own eight-part split of drug discovery technologies.
Rounds confirmed by a company announcement, a press article or a regulatory filing are counted in full. Where no article exists, a round is counted only when at least two recognised databases agree on its date (within one month) and amount (within 5%), and it is marked as low confidence; a round found in a single database stays in the company's history but is left out of totals. For companies that have raised more than $100M, every round counted is backed by an article.
We prioritize company announcements, regulatory filings, investor releases and reliable reporting when establishing a transaction's size, date, stage and participants. The full deal list is historical: a startup that subsequently listed or was acquired may still appear for an eligible earlier private financing. Individual investor checks are not inferred from the overall size of rounds they led. Company partnerships, clinical milestones and technology details add explanatory context but do not enter our venture funding totals unless they meet the deal definition.
A reader may find a different number in an article about AI biotech because that article may include diagnostics, clinical software, older financings, debt, grants or a different country assignment. We make our boundaries explicit and apply them consistently. The most recent calendar month is also incomplete; its activity should not be mistaken for the rhythm of a completed month. This page covers the full window, not just the latest quarter, and the published sums remain conservative when individual amounts are undisclosed.
Key sources include Isomorphic Labs' May 2026 Series B and stated use of capital., Isomorphic Labs' March 2025 external financing., Isomorphic Labs' Lilly and Novartis discovery collaborations., Isomorphic Labs' cross-modality Johnson & Johnson partnership., Xaira Therapeutics' launch and AI drug discovery strategy., Chai Discovery's funding, model research and pharmaceutical collaborations., Chai-2 experimental antibody-design findings, reported as a preprint., Basecamp Research's EDEN platform and September 2026 round., Enveda Biosciences' platform, clinical progress and September 2026 financing., NewLimit's epigenetic reprogramming programs and June 2026 financing., Pathos AI's platform, pipeline and October 2026 financing., Biossil financing and abandoned-drug repurposing approach., Warp Sciences' AI robotics and chemistry-laboratory plans., Chemify's programmable chemistry and closed-loop laboratory technology., Eikon Therapeutics' imaging-driven drug discovery., Soley Therapeutics' cell-stress platform and oncology work., FDA draft guidance on AI credibility for regulatory decisions., FDA and EMA principles on reliable AI in drug development., Insilico Medicine's rentosertib Phase III trial update., NVIDIA's BioNeMo Agent Toolkit and biotech collaborations., United Kingdom's OpenBind project for AI drug discovery., and AlphaFold 3 and research access to molecular structure prediction..

In our report covering the AI drug discovery market, we like to show you the big picture. We know your time is precious, so we make every page quick to read and packed with as much learning as possible per minute.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
